Novel Vector System for Breast Cancer Therapy
Abstract
Experiments outlined in the original statement of work showed that our initial sustained release technology for the delivery of therapeutic adenovirus was not feasible. As a result, we have developed a revised statement of work that entails the development of a controlled release formulation of tumor necrosis factor a (TNF alpha) in combination with an adenovirus that replicates selectively within carcinoma tissue and sensitizes the tumor tissue to TNF alpha. We have succeeded in developing microspheres that release bioactive TNF alpha over more than 1 month. We have also succeeded in obtaining the selectively replicating adenovirus (dl338). We have also succeeded in demonstrating a greater than additive tumoricidal activity in vitro of the TNF alpha combined with the dl338. These experimental successes will be followed in the current year by animal experiments expected to validate this novel therapy for breast carcinoma.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1999
- Accession Number
- ADA385893
Entities
People
- Robert I. Garver
Organizations
- University of Alabama